Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
News|Articles|October 14, 2026

A New Approach to Clinical Trial Planning: How Mid-Market and Emerging Pharma Can Take Greater Control of Patient Enrollment

This executive summary looks at how mid-size and emerging pharma companies can keep greater control of patient enrollment by treating site selection, timeline forecasting, and in-study adaptation as one connected process. Using an illustrative Phase 3 ALK-positive non–small cell lung cancer (NSCLC) trial and a representative five-study portfolio, it shows how the ZAIDYN clinical platform supports each decision with shared, evidence-based data.


Related to this article

What Needs to Happen Beyond the Clinical Trial Modernization Act
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.